Literature DB >> 28524459

Prognostic Role of Conventional and Dynamic Contrast-Enhanced MRI in Optic Pathway Gliomas.

Nutchawan Jittapiromsak1,2, Ping Hou3, Ho-Ling Liu3, Jia Sun4, John M Slopis5, T Linda Chi1.   

Abstract

BACKGROUND AND
PURPOSE: The natural history of optic pathway glioma (OPG) is highly variable and unpredictable. We present a pilot study of the prognostic role of conventional and dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) in the evaluation of OPG.
METHODS: We retrospectively reviewed 17 patients with 20 pretreatment OPG lesions who underwent conventional and DCE MRI between January 2010 and December 2016. Conventional MRI was evaluated for enhancement pattern, cystic component, optic nerve tortuosity, optic nerve dural ectasia, and optic nerve perineural thickening. The DCE MRI data were analyzed for quantitative parameters using the two-compartment pharmacokinetic model (Ktrans , kep , and ve ) and for semiquantitative parameters based on time-signal intensity curve (AUC60 , peak, and wash-in). The results were compared with the clinically progressive or nonprogressive tumor.
RESULTS: Five progressive OPGs and 15 nonprogressive OPGs were included. Conventional MRI findings of diffuse enhancement and cystic component were significantly correlated with progressive OPGs (both P = .01). Conventional MRI yielded sensitivity of 60%, specificity of 100%, and accuracy of 90%. Ktrans , kep , and ve as well as AUC60 , peak, and wash-in were significantly higher in progressive OPGs (P < .05). Using DCE MRI increased diagnostic performance up to a sensitivity of 100%, specificity of 93%, and accuracy of 95%.
CONCLUSION: DCE MRI accurately distinguished progressive and nonprogressive OPGs, with high sensitivities and specificities. DCE MRI has a significant prognostic role in predicting progressive OPGs, thus making it useful for the identification of patients who need close clinical and imaging follow-up.
Copyright © 2017 by the American Society of Neuroimaging.

Entities:  

Keywords:  MRI; Prognostic role; dynamic contrast-enhanced MRI; optic pathway glioma

Mesh:

Substances:

Year:  2017        PMID: 28524459     DOI: 10.1111/jon.12450

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  5 in total

1.  Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?

Authors:  Ezekiel Maloney; A Luana Stanescu; Francisco A Perez; Ramesh S Iyer; Randolph K Otto; Sarah Leary; Lotte Steuten; Amanda I Phipps; Dennis W W Shaw
Journal:  Pediatr Radiol       Date:  2018-05-22

2.  68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma.

Authors:  Jingjing Zhang; Yongji Tian; Deling Li; Gang Niu; Lixin Lang; Fang Li; Yuhan Liu; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-03       Impact factor: 9.236

3.  Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning.

Authors:  Jared M Pisapia; Hamed Akbari; Martin Rozycki; Jayesh P Thawani; Phillip B Storm; Robert A Avery; Arastoo Vossough; Michael J Fisher; Gregory G Heuer; Christos Davatzikos
Journal:  Neurooncol Adv       Date:  2020-08-01

4.  Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.

Authors:  Natalie R Boonzaier; Patrick W Hales; Felice D'Arco; Bronwen C Walters; Ramneek Kaur; Kshitij Mankad; Jessica Cooper; Alki Liasis; Victoria Smith; Patricia O'Hare; Darren Hargrave; Christopher A Clark
Journal:  Neuroimage Clin       Date:  2020-09-28       Impact factor: 4.881

5.  Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.

Authors:  Anna Kilian; Annette Aigner; Michèle Simon; Daniel J Salchow; Cornelia Potratz; Ulrich-Wilhelm Thomale; Pablo Hernáiz Driever; Anna Tietze
Journal:  J Neurooncol       Date:  2022-01-07       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.